$1.91
+0.02 (+1.06%)
Open$1.86
Previous Close$1.89
Day High$1.98
Day Low$1.86
52W High$35.64
52W Low$1.37
Volume—
Avg Volume81.0K
Market Cap3.42M
P/E Ratio—
EPS$-51.32
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+1,379.1% upside
Current
$1.91
$1.91
Target
$28.25
$28.25
$22.50
$28.25 avg
$48.31
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 1.10M | 989.8K | 1.05M |
| Net Income | -234,853 | -218,932 | -208,731 |
| Profit Margin | -21.4% | -22.1% | -19.9% |
| EBITDA | -290,262 | -298,722 | -291,498 |
| Free Cash Flow | -192,766 | -116,937 | -167,359 |
| Rev Growth | -6.5% | +19.5% | +20.8% |
| Debt/Equity | 0.95 | 1.14 | 1.06 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $266.28 | +0.73% | 74.3 | 468.50B |
| AMGN | Amgen Inc | $418.13 | +0.85% | 25.1 | 219.78B |
| GILD | Gilead Sciences Inc | $152.21 | +0.85% | — | 185.02B |
| VRTX | Vertex Pharmaceuticals Inc | $527.67 | +0.28% | 30.5 | 134.17B |
| REGN | Regeneron Pharmaceuticals | $752.25 | -4.54% | 18.8 | 81.31B |
| ALNY | Alnylam Pharmaceuticals Inc | $255.36 | -0.23% | 41.4 | 33.44B |